Continuing the recent trend, four out of five deals priced below the range. This week, five companies raised $765 million, pricing an average of 19% below their proposed midpoints. All four deals that priced below traded up, popping 10% on...read more
CytomX Therapeutics, a preclinical biotech developing tumor-activated cancer immunotherapies, raised $80 million by offering 6.7 million shares at $12, below the range of $14 to $16. CytomX Therapeutics plans to list on the Nasdaq under the symbol CTMX. CytomX...read more
As many as 11 companies could go public this week, including the year's largest IPO (Digicel) and the fastest-growing company (Pure Storage). Both have proposed market caps of more than $3.5 billion, while six others target valuations of $300 million or...read more
CytomX Therapeutics, a preclinical biotech developing tumor-activated cancer immunotherapies, announced terms for its IPO on Monday.
The South San Francisco, CA-based company plans to raise $100 million by offering 6.7 million shares at a price range of $14...read more
US IPO Weekly Recap: Cut the offer price for positive returns
Continuing the recent trend, four out of five deals priced below the range. This week, five companies raised $765 million, pricing an average of 19% below their proposed midpoints. All four deals that priced below traded up, popping 10% on...read more
CytomX Therapeutics prices IPO at $12, below the range
CytomX Therapeutics, a preclinical biotech developing tumor-activated cancer immunotherapies, raised $80 million by offering 6.7 million shares at $12, below the range of $14 to $16. CytomX Therapeutics plans to list on the Nasdaq under the symbol CTMX. CytomX...read more
Week ahead: Fourth quarter kicks off with 11 IPOs set for the week of October 5
As many as 11 companies could go public this week, including the year's largest IPO (Digicel) and the fastest-growing company (Pure Storage). Both have proposed market caps of more than $3.5 billion, while six others target valuations of $300 million or...read more
Cancer immunotherapy biotech CytomX sets terms for $100 million IPO
CytomX Therapeutics, a preclinical biotech developing tumor-activated cancer immunotherapies, announced terms for its IPO on Monday. The South San Francisco, CA-based company plans to raise $100 million by offering 6.7 million shares at a price range of $14...read more